Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Promedior, Inc.

http://www.promedior.com

Latest From Promedior, Inc.

COVID-19 Accounts For Most Of 2020’s Pharma Pipeline Growth

The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.

Companies Research & Development

Finance Watch: VC Mega-Rounds Fund Wide Array, From Respiratory To Rare Diseases

Private Company Edition: China-focused Nuance Pharma led recent venture capital deals with a $181m series D round, RayzeBio closed a $105m series B and SciNeuro launched with $100m plus other notable rounds from Edgewise, Reneo, BioAge and others.

Financing StartUps and SMEs

Boehringer, Bridge IPF Deal Collapses On Toxicity Concerns

The termination of a major idiopathic pulmonary fibrosis collaboration between Bridge Biotherapeutics and Boehringer Ingelheim is a blow to both companies in an increasingly competitive indication, but the Korean biotech says it's still committed to further development of the autotaxin inhibitor and will work out a future development plan.

Commercial Respiratory

Roche Returns To Cystic Fibrosis Fray With Enterprise Deal

While Vertex appears to have the cystic fibrosis market covered with its CFTR modulators, Enterprise has been exploring another channel, TMEM16A, in the hope of developing compounds that could possibly be used by everybody with the lethal genetic disease.

Respiratory Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register